- Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange
- The cannabis business will commence trading on the US market on today (Friday, June 11) under the ticker code COPHF
- CPH says its new listing will better expose the company to North American investors, ahead of its US pharmaceutical market entry
- The company is in the process of acquiring Halucenex, a Canadian business that is involved in researching psychedelics
- Creso Pharma shares are up 12.5 per cent at 18 cents each at 11:18 am AEST
Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The cannabis business will commence trading on the US market today (Friday, June 11) under the ticker code COPHF.
CPH said the new listing would better expose the company to North American investors and align with its plans to enter the region’s pharmaceutical market.
The company is also in the process of acquiring Halucenex, a Canadian business that is involved in researching psychedelics
“The company’s dual listing coincides with the growth Creso Pharma has achieved recently in the US and North America more broadly,” Non-Executive Chairman Adam Blumenthal said.
Mr Blumenthal explained CPH had already assigned John Griese as its American leader to help navigate the US market entry.
“Recently, we have been focused on laying a very strong foundation in the region, which is underpinned by the expansion of operations and key appointments that will provide a number of value catalysts for both Australian and North American investors,” Mr Blumenthal said.
“The cannabis and psychedelic medicines sectors continue to gain considerable momentum.
“Recent regulatory shifts have left the company in a favourable position and Creso is well placed to become a global leader across both sectors.”
Following today’s announcement, Creso Pharma shares were up 12.5 per cent at 18 cents each at 11:18 am AEST.